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Abstract
The recently cloned extracellular calcium-sensing receptor (CaR) is a
G protein-coupled receptor that plays an essential role in the regula-
tion of extracellular calcium homeostasis. This receptor is expressed
in all tissues related to this control (parathyroid glands, thyroid C-
cells, kidneys, intestine and bones) and also in tissues with apparently
no role in the maintenance of extracellular calcium levels, such as
brain, skin and pancreas. The CaR amino acid sequence is compatible
with three major domains: a long and hydrophilic aminoterminal
extracellular domain, where most of the activating and inactivating
mutations described to date are located and where the dimerization
process occurs, and the agonist-binding site is located, a hydrophobic
transmembrane domain involved in the signal transduction mechan-
ism from the extracellular domain to its respective G protein, and a
carboxyterminal intracellular tail, with a well-established role for cell
surface CaR expression and for signal transduction. CaR cloning was
immediately followed by the association of genetic human diseases
with inactivating and activating CaR mutations: familial hypocalciuric
hypercalcemia and neonatal severe hyperparathyroidism are caused by
CaR-inactivating mutations, whereas autosomal dominant hypopara-
thyroidism is secondary to CaR-activating mutations. Finally, we will
comment on the development of drugs that modulate CaR function by
either activating (calcimimetic drugs) or antagonizing it (calcilytic
drugs), and on their potential therapeutic implications, such as medi-
cal control of specific cases of primary and uremic hyperparathyroid-
ism with calcimimetic drugs and a potential treatment for osteoporosis
with a calcilytic drug.
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Introduction: an overview of
structural and functional features
of the extracellular calcium-sensing
receptor
The extracellular calcium-sensing recep-
tor (CaR) was cloned by Brown et al. (1) in
1993 from bovine parathyroid glands. The
cloning of this receptor provided valuable
information regarding mechanisms related
to the control of extracellular calcium ho-
meostasis. Until 1993, hormones such as
parathormone (PTH), 1,25-dihydroxyvitamin
D3 and calcitonin, interacting with their re-
spective target organs and tissues involved in
the regulation of calcium homeostasis, were
promptly recognized as major participants in
the adequate maintenance of this delicate
balance. However, the presumed common
mechanism responsible for the sensing of
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minor variations in extracellular calcium
concentration could be only successfully
identified with the cloning of the CaR (1).
In fact, many papers subsequently dem-
onstrated the expression of the CaR in all the
tissues directly related to the control of cal-
cium homeostasis: human and chicken para-
thyroid glands; rat, human and rabbit kid-
ney; thyroid rat and human C-cells; human
and rat intestine, and also in diverse bone
marrow-derived cells (2,3). With this in mind,
it is currently accepted that, in addition to
serving as an intracellular second messen-
ger, calcium ion also plays a hormone-like
role as an extracellular first messenger (4).
In this context, there is no doubt that the CaR
plays an essential role in the regulation of
extracellular calcium homeostasis, mainly
by mediating the inhibitory actions of extra-
cellular calcium on parathyroid hormone se-
cretion by the parathyroid glands and by
influencing the rates of renal tubular calcium
reabsorption and secretion of calcitonin by
thyroidal C-cells. In addition to all these
tissues directly involved in the calcium ho-
meostatic system, the CaR seems to be widely
distributed, being expressed in tissues with
apparently no evident role in the control of
Figure 1. Schematic diagram of the human extracellular calcium-sensing receptor (hCaR) showing the amino acid
sequence of the large hCaR extracellular domain. The location of the N-linked glycosylation sites is shown and all
the 19 cysteines are shown inside black circles. The beginning and the end of the putative “venus flytrap” (VFT)
domain are indicated. The cysteine-rich domain includes the nine cysteine residues located between C542 and
C598.
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extracellular calcium homeostasis, such as
breast, keratinocytes, a variety of cells within
the central nervous system, pancreas, and
lens epithelial cells (2). The specific roles of
the CaR in all these tissues still remain to be
elucidated.
Structurally speaking, the human homo-
logue of the CaR is a G protein-coupled
receptor (GPCR) consisting of 1078 amino
acid residues (3). The first 612 amino acids
are included in a large extracellular domain
(ECD), which is a feature of the subfamily to
which the CaR belongs. In addition to the
CaR, this subfamily of GPCRs (also called
family C or family 3) includes the metabo-
tropic glutamate receptors (5), putative phero-
mone receptors in the vomeronasal organ (6-
8), putative taste receptors (9) and GABAB
receptors (10).
Part of this large ECD (from amino acid
residue 36 to amino acid residue 513) seems
to be structurally related to the bilobed
(venus flytrap) structure of bacterial peri-
plasmic binding proteins (11-14) (Figure 1),
and hypothetically the closing of the two
lobes after binding of ligands triggers the
transmission of signals from the ECD to the
receptors cytoplasmic signaling loops. The
CaR ECD is thought to be the site of Ca2+
binding (15,16) and contains 11 potential N-
linked glycosylation sites (17,18) and a total
of 19 cysteines, nine of them being highly
conserved and located at the end of the ECD,
and constituting the so-called cysteine-rich
domain which plays a critical role in signal
transduction from the corresponding venus
flytrap domain to the seven-transmembrane
domain (19) (Figure 1). Recent studies have
demonstrated that the CaR is expressed on
the cell surface as an intermolecular disul-
fide-linked dimer (20,21) and cysteine resi-
dues which are critical for CaR dimerization
have been identified (13,22). Moreover,
heterodimerization of mutant CaRs and in-
termolecular interactions of the heterodimeric
receptor have been shown to be functionally
important for receptor-dependent signaling
(23,24) and recent findings have suggested
that the CaR has at least two distinct types of
motifs mediating dimerization and functional
interactions: covalent interactions involving
intermolecular disulfide bonds and nonco-
valent, possibly hydrophobic, interactions
(22). Most of the natural activating and inac-
tivating mutations described so far are lo-
cated in the ECD (Table 1) and a cluster of
natural and artificial activating mutations is
located between residues Ala116 and Pro136,
suggesting that this region is very important
Table 1. Natural activating and inactivating mutations of the human calcium-sensing
receptor described to date.
Activating mutations Site Inactivating mutations Site
K47N ECD C7-frameshift ECD
A116T ECD Q27R ECD
N118K ECD P39A ECD
L125P ECD P40A ECD
E127A ECD S53P ECD
F128L ECD P55L ECD
C129F ECD R62M ECD
T151M ECD R66C ECD
E191K ECD S137P ECD
P221L ECD T138M ECD
E228Q ECD G143E ECD
Q245R ECD L174R ECD
Q254R ECD N178D ECD
F612S ECD R185Q ECD
Q681H 1st EC loop D215G ECD
L773R TM-5 Y218S ECD
F788C TM-5 R220W ECD
F806S TM-6 P221S ECD
S820F TM-6 R227L(Q) ECD
A835T 3rd EC loop E297K ECD
A843E TM-7 C395R ECD
S895-V1075 C-tail G549R ECD
(in-frame deletion) G552R ECD
C582Y ECD
S607Stop ECD
R648X 1st IC loop
S657Y TM-2
G670R TM-2
R680C 1st EC loop
P747-frameshift 2nd EC loop
P748R 2nd EC loop
R795W 3rd IC loop
V817I TM-6
T876-frameshift C-tail
F881L C-tail
ECD, extracellular domain; EC, extracellular; IC, intracellular; TM, transmembrane
domain; C-tail, carboxyterminal tail.
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for the maintenance of the inactive confor-
mation of the CaR (25).
CaR activation by extracellular calcium
involves activation of phospholipase Cß via
the Gq subfamily of G proteins, with a conse-
quent transient increase of intracellular cal-
cium. Actually, the CaR is thought to couple
through its intracellular loops as well as its
carboxyterminal intracellular tail (C-tail) to
the various G proteins that mediate its bio-
logical actions (including Gq for activating
phospholipase C and Gi for inhibiting aden-
ylate cyclase) (2,4). The functional charac-
teristics of the expressed wild-type CaR are
included in the definition of the EC50 for
extracellular calcium, which is the effective
concentration of extracellular calcium elicit-
ing one half of the maximal intracellular
calcium response. This corresponds to a value
around 4.1 mM in transiently transfected
HEK293 cells (26).
The seven-transmembrane domain, char-
acteristic of the superfamily of GPCRs, is
involved in the signal transduction mechan-
ism from the CaR ECD to its respective G
protein. In addition (see Table 1), natural
activating and inactivating mutations have
been identified in the seven-transmembrane
domain, including the single constitutive ac-
tivating mutation (A843E) of the CaR de-
scribed to date (27). Within the intracellular
domains of the human CaR, there are five
predicted protein kinase C phosphorylation
sites. The C-tail comprises over 200 amino
acid residues and its role for cell surface CaR
expression and for signal transduction has
been described. Moreover, it has been dem-
onstrated that the first 20 amino acid resi-
dues in the membrane-proximal portion of
the C-tail are important for CaR function
(28,29).
Extracellular calcium-sensing
receptor: association with diseases
CaR cloning was promptly followed by
identification of inherited human hypercal-
cemic and hypocalcemic disorders, respec-
tively resulting from loss and gain of func-
tion mutations in the CaR (2,30,31). In fa-
milial hypocalciuric hypercalcemia (FHH)
(32-34) and neonatal severe hyperparathy-
roidism (NSHPT) (35), loss of function mu-
tations in the CaR lead to generalized resis-
tance to extracellular calcium. The opposite
phenotype, hypocalcemia with relative hy-
percalciuria, is associated with a disorder
termed autosomal dominant hypocalcemia
(ADH) (36), which has been shown to be
caused by gain of function mutations in the
CaR leading to hyperresponsiveness to ex-
tracellular calcium.
A list of natural activating and inactivat-
ing mutations described so far (with their
respective locations in the CaR) that are
associated with these diseases is shown in
Table 1. The single exception regarding phe-
notype is an inactivating mutation (F881L)
located in the C-tail which leads to hypercal-
cemia and hypercalciuria (37).
FHH is inherited as an autosomal-domi-
nant trait with a high penetrance of over 90%
(33,34). The majority of families exhibit
linkage of the disease gene to chromosome 3
(band q21-24) known to contain the CaR
gene, but an exception can be illustrated by a
family that showed linkage of a phenotypi-
cally indistinguishable disorder to the short
arm of chromosome 19, band 19p13.3 (38).
FHH is a rare disorder of mineral metabo-
lism characterized by lifelong, mild to mod-
erate but usually asymptomatic hypercalce-
mia. Another feature of this disease is the
presence of inappropriately low rates of uri-
nary calcium excretion (a calcium to creati-
nine clearance ratio of <0.01) and nonsup-
pressed circulating levels of PTH, regardless
of the presence of hypercalcemia (33,34). In
short, the diagnosis of FHH can be estab-
lished by documenting the combination of a
low urinary calcium to creatinine clearance
ratio, a normal PTH level, and the autoso-
mal-dominant inheritance of mild, asympto-
matic hypercalcemia. Consequently and re-
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inforcing the importance of differential di-
agnosis with primary hyperparathyroidism,
surgery (parathyroidectomy) is not indicated
and will not improve the hypercalcemia of
patients with FHH. Impairment of extracel-
lular calcium sensing by the CaR in FHH
patients was proven by functional studies in
which human embryonic kidney (HEK293)
cells were transfected with CaRs bearing
FHH mutations. These studies showed an
increase in EC50 and many mutants also dis-
closed a reduction in maximal activity
(26,29), supporting previous studies regard-
ing formal testing of calcium-regulated PTH
secretion that indicated an increase in set-
point (39).
Due to severe primary hyperparathyroid-
ism with enlargement of all four parathyroid
glands, the degree of hypercalcemia in
NSHPT is usually more severe than that
observed in FHH, and this disorder can be
fatal if parathyroidectomy is not carried out
within the first weeks of life. Bone deminer-
alization, often accompanied by multiple frac-
tures of long bones and ribs may be present.
Some infants with NSHPT represent the ho-
mozygous form of FHH (40), or, as seen in
one case, a compound heterozygote in which
a different inactivating CaR mutation was
inherited from each parent (41). In some
cases, NSHPT may be caused by the pres-
ence of heterozygous inactivating mutations
of the CaR, either in a familial setting or as a
de novo mutation in the offspring of normal
parents, and possibly in these cases the mu-
tant CaR can exert a dominant negative
action, impairing the function of the normal
receptor (42). Recently, mice heterozygous
or homozygous for targeted inactivation of
the CaR gene have been developed. These
mice shared biochemical features of FHH
and NSHPT, supporting the physiological
importance of CaR in mineral ion metabo-
lism (43).
A heterozygous germline activating mis-
sense mutation of the human CaR inhibits
PTH secretion and reduces renal calcium
reabsorption at an inappropriately low se-
rum calcium concentration, leading to hy-
pocalcemia, relative hypercalciuria and an
inappropriately low serum PTH that charac-
terizes subjects with ADH or sporadic hy-
pocalcemia (27,44). Pearce et al. (36) stud-
ied six families with ADH and verified that,
in addition to having asymptomatic hypocal-
cemia with detectable PTH levels, affected
family members also had hypomagnesemia
and hyperphosphatemia. Differently from
what occurs in hypoparathyroidism, there is
resetting of the calcium homeostatic system
downward, maintaining the extracellular cal-
cium at subnormal concentrations. In addi-
tion, a reason for classifying these families
as ADH instead of familial isolated hypo-
parathyroidism is their response to vitamin
D treatment. When an attempt was made to
normalize their serum calcium levels with
calcitriol, marked hypercalciuria with result-
ant nephrocalcinosis was observed in some
cases. Some of them apparently also devel-
oped nephrogenic diabetes insipidus. There-
fore, it seems that the calcium homeostatic
system of these individuals is adjusted to a
lower than normal serum calcium concentra-
tion, and attempts to make them normocal-
cemic result in hypercalcemic manifesta-
tions, such as hypercalciuria and nephro-
genic diabetes insipidus (35). CaR muta-
tions in ADH (36,44), with one single excep-
tion (27), cause increased sensitivity to ex-
tracellular calcium rather than constitutive
activation. Expression of CaRs harboring
activating mutations in HEK293 cells re-
vealed reductions in EC50 of the mutant re-
ceptors (26,44,45).
Extracellular calcium-sensing
receptor: therapeutic implications
The CaR responds to many polycationic
ligands, including divalent and trivalent cat-
ions (i.e., Ca2+, Mg2+, Gd3+) and polyamines
(neomycin and spermine) when expressed in
either Xenopus laevis oocytes or HEK293
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cells (1,26,46). It has been recently shown
that the CaR can be also activated by amino
acids, especially aromatic amino acids, and
this finding may help to explain some ac-
tions of dietary proteins on calcium metabo-
lism (47).
Since the CaR represents a potential thera-
peutic target for disorders in which the re-
ceptor is inappropriately overactive or un-
deractive (48), some compounds have been
developed with the aim of either activating
(calcimimetics) (49) or inactivating (calci-
lytics) (50) the CaR.
A so-called calcimimetic agent NPS R-
568 (49) has been shown to actually increase
CaR sensitivity to Ca2+ and this action has
been demonstrated to successfully inhibit
PTH secretion in vitro and in subjects with
primary hyperparathyroidism (51), includ-
ing a patient with parathyroid carcinoma
(52), and also in rats and patients with ure-
mic hyperparathyroidism (53,54). In primary
hyperparathyroidism, oral NPS R-568 pro-
duces fast (within minutes) and substantial
(>50%) decreases in circulating PTH, fol-
lowed hours later by reductions in serum
calcium concentration at higher doses. In
this context, this calcimimetic resets the el-
evated set-point of pathological parathyroid
glands toward normal (2). As expected, a
short-term use of this calcimimetic was also
associated with an increase in urinary cal-
cium excretion in hypercalcemic patients
with primary hyperparathyroidism (51), sug-
gesting that a CaR antagonist could be very
useful for the treatment of calcium-contain-
ing renal stones. The site of action of R-568
appears to be within and specific for the
seven-transmembrane domain of the CaR
(45).
Based on previous studies (55,56) show-
ing that PTH is a potential anabolic agent for
the bone and consequently a promising drug
for the management of osteoporosis, Gowen
et al. (50) recently studied the effects of
antagonizing the parathyroid calcium recep-
tor with the use of a so-called calcilytic drug
(termed NPS 2143) in osteopenic ovariecto-
mized rats. These authors observed an in-
crease in endogenous PTH secretion leading
to a significant increase in bone turnover.
These preliminary results suggest that this or
future similar drugs may be potential candi-
dates for the treatment of osteoporosis. Fu-
ture understanding of the functions of the
expressed CaR in tissues with apparently no
kind of role in the maintenance of extracellu-
lar calcium levels may suggest additional
therapeutic roles for CaR agonists or antago-
nists (2).
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